FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283403> ?p ?o ?g. }

• W4379283403 endingPage "10002" @default.
• W4379283403 startingPage "10002" @default.
• W4379283403 abstract "10002 Background: Aggressive therapies for high-risk neuroblastoma (HRNBL) have resulted in increased survival, but late effects have not been well-characterized. Methods: Comprehensive cross-sectional evaluation of health outcomes in HRNBL survivors enrolled on the COG Neuroblastoma Biology Study after 1/1/2000 and ≥ 5 years from primary diagnosis, using medical record abstraction and in-person clinical assessments. Descriptive and multivariable analyses identified extent of and risk factors for late toxicity. Results: There were 375 participants from 88 COG centers, 205 (55%) male; 92 (26%) non-white; 45 (13%) Hispanic. Median age at neuroblastoma diagnosis was 2.5 years (range: 0.2-15.8), at enrollment was 12.0 years (range: 5.0-24.0). All had received chemotherapy; 94% received cisplatin (median dose: 398 mg/m2). Other exposures included: radiation (95%), isotretinoin (91%), anti-GD2 antibody therapy (64%), MIBG (7%), single (79%) or tandem autologous transplantation (ASCT; 20%). ASCT conditioning included: Busulfan/Melphalan (BuMel) (18%), Carboplatin/Etoposide/Melphalan (CEM) (73%), Thiotepa/Cytoxan (19%), and total body irradiation (5%). Severe ototoxicity (requiring hearing aids) was observed in 58% of participants. Physician-reported late effects included hypothyroidism (17%), pulmonary hypertension (1%), congestive heart failure (2%), and hypertension (6%). Pulmonary Function Studies revealed restrictive lung disease [RLD - Total Lung Capacity < 70% predicted] in 8% of subjects. Laboratory study showed elevated creatinine in 7% and Hemoglobin A1c in 7%. Growth failure (height Z-score < -1.7) was observed in 34%. Subsequent malignant neoplasms (SMN) developed in 15 participants (4%; 4 sarcomas, 3 MDS/t-AML, single instance of 8 other malignancies). Adjusting for sex, follow-up time, age, and race, there were no differences in risk of SMN, severe ototoxicity, growth failure, or RLD for participants who received BuMel vs. CEM-based condtioning, or among those who received anti-GD2 antibody therapy vs. those who did not. Use of carboplatin during ASCT was not assocoiated with increased ototoxicity risk for any category of cisplatin induction dose. Comparing subjects who received CEM as a component of tandem ASCT (vs. single CEM), there was increased risk of growth failure [OR (95%CI) = 4.2(2.1, 8.4); p < 0.0001], but not RLD. Exposure to isotretinoin was not associated with increased risk of growth failure. Further multivariable analyses will be presented, exploring risks for late toxicity associated with conditioning regimens, radiation therapy, surgical approaches, and acute and chronic complications of therapy. Conclusions: The burden of late toxicity in HRNBL survivors is substantial. Anti-GD2 immunotherapy and isotretinoin do not appear to be associated with SMN, ototoxicity, growth failure, or RLD." @default.
• W4379283403 created "2023-06-05" @default.
• W4379283403 creator A5000459362 @default.
• W4379283403 creator A5003639088 @default.
• W4379283403 creator A5013064011 @default.
• W4379283403 creator A5016016418 @default.
• W4379283403 creator A5017501517 @default.
• W4379283403 creator A5020759638 @default.
• W4379283403 creator A5039048640 @default.
• W4379283403 creator A5042736213 @default.
• W4379283403 creator A5045621426 @default.
• W4379283403 creator A5051664972 @default.
• W4379283403 creator A5053168617 @default.
• W4379283403 creator A5064372210 @default.
• W4379283403 creator A5067398740 @default.
• W4379283403 creator A5079552409 @default.
• W4379283403 creator A5084390679 @default.
• W4379283403 date "2023-06-01" @default.
• W4379283403 modified "2023-09-25" @default.
• W4379283403 title "A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study." @default.
• W4379283403 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.10002" @default.
• W4379283403 hasPublicationYear "2023" @default.
• W4379283403 type Work @default.
• W4379283403 citedByCount "0" @default.
• W4379283403 crossrefType "journal-article" @default.
• W4379283403 hasAuthorship W4379283403A5000459362 @default.
• W4379283403 hasAuthorship W4379283403A5003639088 @default.
• W4379283403 hasAuthorship W4379283403A5013064011 @default.
• W4379283403 hasAuthorship W4379283403A5016016418 @default.
• W4379283403 hasAuthorship W4379283403A5017501517 @default.
• W4379283403 hasAuthorship W4379283403A5020759638 @default.
• W4379283403 hasAuthorship W4379283403A5039048640 @default.
• W4379283403 hasAuthorship W4379283403A5042736213 @default.
• W4379283403 hasAuthorship W4379283403A5045621426 @default.
• W4379283403 hasAuthorship W4379283403A5051664972 @default.
• W4379283403 hasAuthorship W4379283403A5053168617 @default.
• W4379283403 hasAuthorship W4379283403A5064372210 @default.
• W4379283403 hasAuthorship W4379283403A5067398740 @default.
• W4379283403 hasAuthorship W4379283403A5079552409 @default.
• W4379283403 hasAuthorship W4379283403A5084390679 @default.
• W4379283403 hasConcept C126322002 @default.
• W4379283403 hasConcept C141071460 @default.
• W4379283403 hasConcept C143998085 @default.
• W4379283403 hasConcept C2776694085 @default.
• W4379283403 hasConcept C2777408962 @default.
• W4379283403 hasConcept C2778239845 @default.
• W4379283403 hasConcept C2778684742 @default.
• W4379283403 hasConcept C2780611847 @default.
• W4379283403 hasConcept C2781451048 @default.
• W4379283403 hasConcept C2911091166 @default.
• W4379283403 hasConcept C71924100 @default.
• W4379283403 hasConceptScore W4379283403C126322002 @default.
• W4379283403 hasConceptScore W4379283403C141071460 @default.
• W4379283403 hasConceptScore W4379283403C143998085 @default.
• W4379283403 hasConceptScore W4379283403C2776694085 @default.
• W4379283403 hasConceptScore W4379283403C2777408962 @default.
• W4379283403 hasConceptScore W4379283403C2778239845 @default.
• W4379283403 hasConceptScore W4379283403C2778684742 @default.
• W4379283403 hasConceptScore W4379283403C2780611847 @default.
• W4379283403 hasConceptScore W4379283403C2781451048 @default.
• W4379283403 hasConceptScore W4379283403C2911091166 @default.
• W4379283403 hasConceptScore W4379283403C71924100 @default.
• W4379283403 hasFunder F4320308906 @default.
• W4379283403 hasIssue "16_suppl" @default.
• W4379283403 hasLocation W43792834031 @default.
• W4379283403 hasOpenAccess W4379283403 @default.
• W4379283403 hasPrimaryLocation W43792834031 @default.
• W4379283403 hasRelatedWork W2001025108 @default.
• W4379283403 hasRelatedWork W2023755033 @default.
• W4379283403 hasRelatedWork W2031971852 @default.
• W4379283403 hasRelatedWork W2167270265 @default.
• W4379283403 hasRelatedWork W2339129078 @default.
• W4379283403 hasRelatedWork W2511480447 @default.
• W4379283403 hasRelatedWork W2530463753 @default.
• W4379283403 hasRelatedWork W2562368003 @default.
• W4379283403 hasRelatedWork W2592061165 @default.
• W4379283403 hasRelatedWork W4315701489 @default.
• W4379283403 hasVolume "41" @default.
• W4379283403 isParatext "false" @default.
• W4379283403 isRetracted "false" @default.
• W4379283403 workType "article" @default.